News

Robert Ward appointed as Activation Capital’s interim president and chief executive officer

The Virginia Biotechnology Research Park Authority Board appointed Robert Ward as interim president and chief executive officer of Activation Capital, an innovation ecosystem development organization, effective today. Ward is a senior executive with over 25 years of experience leading organizations, driving strategy and innovation, developing high performing teams and executing complex transactions.

Ward has served as Virginia’s chief transformation officer where he supported agency secretaries with technologies to improve their operations. And prior to that, he was senior adviser to Gov. Glenn Youngkin.

“We are excited to welcome Rob Ward as interim CEO of Activation Capital,” said VCU President and Activation Capital board chair Michael Rao. “Rob brings extensive experience in corporate real estate and strategic development in his career at Skanska, a background that will help us advance Activation Capital’s mission and capital project priorities. As a Virginia Tech alumnus and Virginia resident, Rob understands Virginia and our strengths as an ideal location to grow pharmaceutical manufacturing and innovative biotechnology industries.”

Ward previously was the president and CEO for Skanska Commercial Development U.S., where he set the strategic direction of the company while driving continuous improvement through operational effectiveness, efficiency, and innovation. As CEO, he had responsibility for the investment, development, and construction of more than $4.5B of commercial and residential assets across the country.

Prior to becoming CEO, he served as the COO for the organization where he led the U.S. Investment Committee as well as the Strategic Services Team which included product innovation, technology, customer strategy, systems optimization, operational excellence, portfolio management and construction. Prior to his role as COO, Robert had direct oversight of offices/operations in the mid-Atlantic region, Houston, Texas and Los Angeles, California.

His career at Skanska began in the commercial construction division. He served on the executive leadership teams in both the mid-Atlantic and Southeast U.S. markets where he focused on life science, pharmaceutical, higher education, and federal government construction projects.

“I want to thank outgoing CEO Chandra Briggman for her leadership and I look forward to furthering Activation Capital’s mission and priorities as interim CEO,” Ward said. As the search continues for a CEO, I am committed to growing and fostering Activation Capital’s venture, ecosystem and pharmaceutical cluster development.”

Ward has served on real estate development and construction boards in the United States, Central Europe, the Nordics and the United Kingdom.

Ward is a graduate of Virginia Tech and an emeritus member of the Advisory Board for the Virginia Tech Program in Real Estate. He is a member of the Economic Club of Washington D.C. and has served on the Board of Directors for The First Tee.

Ward replaces Chandra Briggman, who resigned earlier this month after serving in the role since May 2020.

 

Read more here.

Recent News

04/24/2026

Skyphos Technologies Has Been Awarded its Second U.S. Patent

Skyphos Technologies has been awarded its second U.S. patent, adding to a growing intellectual property portfolio that now includes nearly a dozen patent applications in process around the world. This latest patent secures core technologies and methods that allow micro-scale parts to be produced in seconds, at throughputs designed to exceed legacy manufacturing such as

04/23/2026

CollectiveMinds LLC Places Keith Meadors as Chief Commercial Officer at Genova Diagnostics

CollectiveMinds LLC, a leading executive search firm specializing in life sciences and healthcare, today announced the successful placement of Keith Meadors as Chief Commercial Officer of Genova Diagnostics, a pioneer in advanced diagnostic testing. The appointment marks another milestone for CollectiveMinds in connecting exceptional leadership talent with high-growth organizations across the diagnostics and life sciences

04/22/2026

RIVANNA expands multi-site clinical study for Accuro XV musculoskeletal imaging system

RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical studies evaluating Accuro® XV, the company’s musculoskeletal imaging system, from two to eight sites nationwide. This expansion follows execution of a funding option by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response